Tuberous Sclerosis Complex Pipeline Insight 2020


Tuberous Sclerosis Complex Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Tuberous Sclerosis Complex market. A detailed picture of the Tuberous Sclerosis Complex pipeline landscape is provided, which includes the disease overview and Tuberous Sclerosis Complex treatment guidelines.

The assessment part of the report embraces in-depth Tuberous Sclerosis Complex commercial assessment and clinical assessment of the Tuberous Sclerosis Complex pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Tuberous Sclerosis Complex collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Traumatic Brain Injury Pipeline
Traumatic Brain Injury Pipeline

Click Here For Free Sample Page:

Tuberous Sclerosis Complex of pipeline development activities

The report provides insights into:

  • All of the companies that are developing therapies for the treatment of Tuberous Sclerosis Complex with aggregate therapies developed by each company for the same.
  • Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Tuberous Sclerosis Complex treatment.
  • Tuberous Sclerosis Complex key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Tuberous Sclerosis Complex market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.

Tuberous Sclerosis Complex Analytical Perspective by DelveInsight

  • In-depth Tuberous Sclerosis Complex Commercial Assessment of products 

This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.

  • Tuberous Sclerosis Complex Clinical Assessment of products 

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

Scope of the report

  • The Tuberous Sclerosis Complex report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Tuberous Sclerosis Complex across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Tuberous Sclerosis Complex therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Tuberous Sclerosis Complex research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Tuberous Sclerosis Complex.



  • Approximately, 2.8 million people sustain TBI annually in the United States and every day 153 people in the United States die from injuries that include TBI as per Brain line organization.
  • Centers for Disease Control and Prevention reported that over the span of six years (2007–2013) TBI- related ED visits have increased by 47%, hospitalization rates decreased by 2.5% and death rates decreased by 5%.
  • Marek Majdan et al. estimated that about 57,000 TBI-related deaths and 1·5 million hospital discharges occurred in 2012 in Europe.
  • According to data from the Overall Analysis Center of Traffic Accidents, TBI accounts for 9.3% of 1,160,000 traffic.



  • Vasopharm GmBH
  • NeuroVive Pharmaceutical AB
  • Cellvation Therapeutics



  • Ronopterin (VAS203)
  • NeuroSTAT
  • CEVA101


Table of content

1. Report Introduction

2. Tuberous Sclerosis Complex 

2.1. Overview

2.2. History

2.3. Tuberous Sclerosis Complex Symptoms

2.4. Causes

2.5. Pathophysiology

2.6. Tuberous Sclerosis Complex Diagnosis

2.6.1. Diagnostic Guidelines

3. Tuberous Sclerosis Complex Current Treatment Patterns

3.1. Tuberous Sclerosis Complex Treatment Guidelines

4. Tuberous Sclerosis Complex – DelveInsight’s Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. Tuberous Sclerosis Complex companies collaborations, Licensing, Acquisition -Deal Value Trends Assessment Summary

4.1.2. Tuberous Sclerosis Complex Collaboration Deals Company-Company Collaborations (Licensing / Partnering) Analysis Company-University Collaborations (Licensing / Partnering) Analysis Tuberous Sclerosis Complex Acquisition Analysis

5. Therapeutic Assessment

5.1. Clinical Assessment of Pipeline Drugs

5.1.1. Assessment by Phase of Development

5.1.2. Assessment by Product Type (Mono / Combination) Assessment by Stage and Product Type

5.1.3. Assessment by Route of Administration Assessment by Stage and Route of Administration

5.1.4. Assessment by Molecule Type Assessment by Stage and Molecule Type

5.1.5. Assessment by MOA Assessment by Stage and MOA

5.1.6. Assessment by Target Assessment by Stage and Target

6. Tuberous Sclerosis Complex Late Stage Products (Phase-III)

7. Tuberous Sclerosis Complex Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Tuberous Sclerosis Complex Discontinued Products

13. Tuberous Sclerosis Complex Product Profiles

13.1. Drug Name: Company

13.1.1. Product Description Product Overview Mechanism of action

13.1.2. Research and Development Clinical Studies

13.1.3. Product Development Activities Collaboration Agreements Acquisition Patent Detail

13.1.4. Tabulated Product Summary General Description Table

14. Tuberous Sclerosis Complex Key Companies

15. Tuberous Sclerosis Complex Key Products

16. Dormant and Discontinued Products

16.1. Dormant Products

16.1.1. Reasons for being dormant

16.2. Discontinued Products

16.2.1. Reasons for the discontinuation

17. Tuberous Sclerosis Complex Unmet Needs

18. Tuberous Sclerosis Complex Future Perspectives

19. Tuberous Sclerosis Complex Analyst Review  

20. Appendix

21. Report Methodology

21.1. Secondary Research

21.2. Expert Panel Validation

22. About DelveInsight 

Related Reports


DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical, Bio-Tech and Medical devices companies formulate prudent business decisions for improving their performances to stay ahead of the competitors.


Shruti Thakur
[email protected]

Related posts